If you enjoy this content, please share it with a colleague
Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
RELATED CONTENT
Elekta's Versa HD system is making its clinical debut or preparing to treat patients at three Australian centers. On Oct. 1, 2014, Macarthur Cancer Therapy Centre at Campbelltown Hospital (Campbelltown, NSW) became the first clinic in Australia to treat patients on one of its two Versa HD systems. On Nov. 10, Adelaide Radiotherapy Centre followed suit with its first Versa HD patient treatments. Nelune Comprehensive Cancer Centre at Prince of Wales Hospital (Randwick, NSW) is making preparations to begin treating patients on its Versa HD system.
Elekta has entered into an agreement with Acumyn Inc. to commercialize its integrated Quality Management System, Aqua.
In their efforts to better integrate the radiation therapy treatment and planning systems of multiple providers, clinicians at Hong Kong Sanatorium & Hospital replaced their Varian ARIA oncology information system (OIS) with Elekta's Mosaiq OIS. Integrated with the hospital's Varian and Accuray linear accelerators and treatment planning systems, Mosaiq went live at the medical center in August.
Men with prostate cancer will be the first group of patients in China to benefit from the recent clearance of Elekta's Clarity soft tissue visualization system by the China Food and Drug Administration (CFDA). As part of Elekta's premiere linear accelerator offering, Versa HD, Clarity enables clinicians to use non-ionizing ultrasound technology to non-invasively image the prostate and surrounding soft tissues before patients begin treatment.
According to a survey by KLAS, an independent research firm, Elekta's Mosaiq Oncology Information System earned the No. 1 ranking in the medical and/or radiology oncology category of KLAS' "Oncology 2014: Integration is Key" report.
The American Society of Radiologic Technologists (ASRT) Foundation announced that the Elekta Radiation Therapy Scholarship has been renewed through 2019.
Elekta's Clarity 4-D prostate monitoring system can now automatically interrupt, or "gate," the radiation beam when it detects that the prostate has moved out of position. Clarity 4-D Monitoring software has enabled doctors to continuously visualize the prostate's precise location during radiation therapy. U.S. Food and Drug Administration (FDA) 510(k) clearance for Clarity to be used with Elekta's Response gating interface will give United States physicians the potential to further safeguard the patient's normal tissues from overexposure to radiation during prostate radiotherapy. The feature is available as an option with Elekta's advanced Versa HD radiation therapy treatment system.
September 11, 2014 — Elekta is showcasing its Elekta Knowledge Management software, a cloud-based software platform for healthcare providers to gain actionable insight from data, at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), Sept. 14-17.
Arc-based radiation therapy continues to gain ground as physicians opt for treatment options that not only are more precisely tailored to each tumor site, but also delivered in fewer visits, which is significantly more convenient for both patients and cancer centers. With a variety of radiation therapy techniques available, from intensity-modulated radiation therapy (IMRT) and whole-body irradiation (WBI) to proton therapy and stereotactic body radiation therapy (SBRT), cancer centers around the country are now, more than ever, able to offer patients a more effective solution for targeting and treating their diseases.